

# MicroRNAs, senescence et vieillissement




Dr Brondello Jean-Marc, INSERM U1183  
Cellules souches et pathologies osteo-articulaires  
St Eloi, IRMB, Montpellier  
[Jean-marc.brondello@inserm.fr](mailto:Jean-marc.brondello@inserm.fr)

# La révolution autour des microARNs



# De la petunias aux patients



**1990**

Researchers insert extra RNA into petunias to make them deeper purple but got pure white, suggesting the existence of an unknown gene-silencing mechanism (Napoli et al)

**1993**

Discovery of lin-4 microRNA, which guides development of the *C. elegans* worm (Ambros et al)

**1998**

RNA interference is discovered in *C. elegans*, solving the petunia puzzle

**2000**

The presence of microRNAs in human cells is established

**2001**

Hundreds of new microRNAs are discovered in animals and plants

**2006**

Nobel Prize: **Andrew Z. Fire, Craig C. Mello**

**2008**

1<sup>st</sup> clinical trial of microRNA-based therapeutic drug: antago-miR122 in liver infection by HCV

**1990**





**1995**



**2000**

**2005**


**2010**



## Processing des miRs

- 15% des Mirs sont en cluster
- 60% des Mirs ont leur propre promoteur
- 25% sont des mitrons

## Répression de la traduction



## Dégradation des ARNm



Dans le génome on retrouverait environ

1-1400 miRs

2-Entre 25 et 50% des gènes seraient régulés par des Mirs


3-Les Mirs induisent une dégradation d' ARNm dans 20-30% des cas

4-Dans le reste des cas, les miRs bloquent la traduction

# Pairing microRNA/mRNA



Ex:



3'UTR mRNA target sequence



miRNA seed sequence  
(positions 2–8)

Le pairing en 3'UTR a permis le développement de logiciels de prédictions des cibles des Mirs

Ex: targetscan/miranda/RNA22/Diana etc.....

### **Conséquences:**

Les publications récentes se basent sur les prédictions de plusieurs de ces logiciels

Mais.....

## ARTICLES

---


# Argonaute HITS-CLIP decodes microRNA–mRNA interaction maps

Sung Wook Chi<sup>1</sup>, Julie B. Zang<sup>1</sup>, Aldo Mele<sup>1</sup> & Robert B. Darnell<sup>1</sup>

MicroRNAs (miRNAs) have critical roles in the regulation of gene expression; however, as miRNA activity requires base pairing with only 6–8 nucleotides of messenger RNA, predicting target mRNAs is a major challenge. Recently, high-throughput sequencing of RNAs isolated by crosslinking immunoprecipitation (HITS-CLIP) has identified functional protein–RNA interaction sites. Here we use HITS-CLIP to covalently crosslink native argonaute (Ago, also called Eif2c) protein–RNA complexes in mouse brain. This produced two simultaneous data sets—Ago–miRNA and Ago–mRNA binding sites—that were combined with bioinformatic analysis to identify interaction sites between miRNA and target mRNA. We validated genome-wide interaction maps for miR-124, and generated additional maps for the 20 most abundant miRNAs present in P13 mouse brain. Ago HITS-CLIP provides a general platform for exploring the specificity and range of miRNA action *in vivo*, and identifies precise sequences for targeting clinically relevant miRNA–mRNA interactions.



**9**




Les dogmes concernant les cibles des miRs en 3'UTR sont à prendre avec précaution

# Conclusions I

- Domaine en évolution permanente
- Interrogation sur les analyses in silico d'identification de cibles
- Possible interférence d'un miR sur plusieurs voies de signalisation ou de mécanismes cellulaires
- Rôle des SNP sur les miRs (ou leurs cibles), permet d'expliquer leur rôle dans plusieurs populations à risque à développer une pathologie donnée


Maintien de la stabilité génétique

Mécanismes anti-vieillessement  
Ou mécanismes de longévité



Métabolisme de l'ADN

↓  
Vieillessement cellulaire, perte de fonctions



**Pathologies de vieillissement prématuré:**

- Werner syndrome
- ataxia telegenectasia
- Dyskerotosis congenita

↓  
induit la dégénérescence des tissus,

↓  
Apparition de pathologies liées à l'âge  
(arthérosclérose, arthrose, hyperplasie de la prostate, Ulcération, peau, immunité, cancer)




↓  
Vieillessement de l'organisme




**Environmental Factors**  
(mechanical stress, Cytokines, Uvs, oncogene)

**intrinsic Factors**  
(oxidative stress- DNA repair defects, erosion des télomères)


Cellular Senescence








# Consequences of senescent cells on tissue



*Senescent cells seem to contribute to age-related decline in tissue structure and function*

# Mirs et senescence cellulaire







- **Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence**

**in MEF**

- Rajini Mudhasani,<sup>1</sup> Zhiqing Zhu,<sup>1</sup> Gyorgy Hutvagner,<sup>2</sup> Christine M. Eischen,<sup>4</sup> Stephen Lyle,<sup>3</sup> Lisa L. Hall,<sup>1</sup> Jeanne B. Lawrence,<sup>1</sup> Anthony N. Imbalzano,<sup>1</sup> and Stephen N. Jones<sup>1,3</sup>

- J. Cell Biol. Vol. 181 No. 7 1055–1063





# Role of MicroRNA Processing in Adipose Tissue in Stress Defense and Longevity

Marcelo A. Mori,<sup>1</sup> Prashant Raghavan,<sup>2</sup> Thomas Thomou,<sup>1,3</sup> Jeremie Boucher,<sup>1</sup> Stacey Robida-Stubbs,<sup>2</sup> Yazmin Macotela,<sup>1</sup> Steven J. Russell,<sup>1</sup> James L. Kirkland,<sup>3</sup> T. Keith Blackwell,<sup>2</sup> and C. Ronald Kahn<sup>1,\*</sup>

<sup>1</sup>Section on Integrative Physiology and Metabolism

<sup>2</sup>Section on Islet Cell and Regenerative Biology


Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA

<sup>3</sup>Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, USA

\*Correspondence: [c.ronald.kahn@joslin.harvard.edu](mailto:c.ronald.kahn@joslin.harvard.edu)

<http://dx.doi.org/10.1016/j.cmet.2012.07.017>





## Inactivation de dicer induit la senescence d'adipocytes in vitro





# Régulation de MKK4 par plusieurs Mirs

Increased MKK4 abundance with replicative senescence is linked to the joint reduction of multiple microRNAs  
 Bernard S. Marasa,<sup>1</sup> Subramanya Srikantan,<sup>1</sup> Kiyoshi Masuda,<sup>1</sup> Kotb Abdelmohsen,<sup>1</sup> Yuki Kuwano,<sup>1</sup> Xiaoling Yang,<sup>1</sup>

Jennifer L. Martindale,<sup>1</sup> Carrie W. Rinker-Schaeffer,<sup>2</sup> and Myriam Gorospe [Sci Signal. 2009 October 27; 2\(94\): ra69.](#)





# Mirs et senescence cellulaire

Causal



Induit à lui seul la sénescence  
B-galactosidase  
Cell cycle arrest  
DNA Damage  
SAPS

Maintenance



Dérégulation de ce miR  
reverte la senescence

# A Genetic Screen Implicates miRNA-372 and miRNA-373 As Oncogenes in Testicular Germ Cell Tumors

P. Mathijs Voorhoeve,<sup>1,5</sup> Carlos le Sage,<sup>1,5</sup> Mariette Schrier,<sup>1</sup> Ad J.M. Gillis,<sup>2</sup> Hans Stoop,<sup>2</sup> Remco Nagel,<sup>1</sup> Ying-Poi Liu,<sup>1</sup> Josyanne van Duijse,<sup>1</sup> Jarno Drost,<sup>1</sup> Alexander Griekspoor,<sup>1</sup> Eitan Zlotorynski,<sup>1</sup> Norikazu Yabuta,<sup>4</sup> Gabriella De Vita,<sup>3</sup> Hiroshi Nojima,<sup>4</sup> Leendert H.J. Looijenga,<sup>2</sup> and Reuven Agami<sup>1,\*</sup>

<sup>1</sup> Division of Tumour Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

<sup>2</sup> Department of Pathology, Erasmus University Medical Center Rotterdam, Daniel den Hoed Cancer Center, Josephine Nefkens Institute, Rotterdam, The Netherlands

<sup>3</sup> Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università Federico II, CEINGE Biotechnologie Avanzate, Naples, Italy


<sup>4</sup> Department of Molecular Genetics, Osaka University, Japan

<sup>5</sup> These authors contributed equally to this work.


\*Contact: [r.agami@nki.nl](mailto:r.agami@nki.nl)

DOI 10.1016/j.cell.2006.02.037


A




C



11





H






# En résumé






# Exemple: pathologies osteo-articulaire associées à l'âge



Pathologies ostéo-articulaires du sujet âgé associant la sénescence cellulaire et la perte de l'homéostasie des tissus


# Osteoarthritis: an age-related disease



- Localization: Knees, hands and hips
- Not only age, but others factors are involved in OA predisposition: such as genetics factors or obesity ...



II-1 $\beta$



Senescence-like phenotype of chondrocytes


Cartilage premature aging with expression of p16<sup>ink4a</sup> (loss of function)


Osteoarthritis

## How to identify miR deregulated in OA ?




We treated human primary chondrocytes with IL-1 $\beta$  cytokine in order to reproduce the major senescent phenotypes associated with OA






Senescence-like phenotypes of chondrocytes treated by IL-1b

## p16<sup>INK4a</sup> overexpression is sufficient to induce MMP1 and MMP13








Senescence-like phenotype  
of chondrocytes

## Analyse des puces


A




Gene	Expression
miR-24-1	Downregulated
miR-24-2	Downregulated
miR-24-3	Downregulated
miR-24-4	Downregulated
miR-24-5	Downregulated
miR-24-6	Downregulated
miR-24-7	Downregulated
miR-24-8	Downregulated
miR-24-9	Downregulated
miR-24-10	Downregulated
miR-24-11	Downregulated
miR-24-12	Downregulated
miR-24-13	Downregulated
miR-24-14	Downregulated
miR-24-15	Downregulated
miR-24-16	Downregulated
miR-24-17	Downregulated
miR-24-18	Downregulated
miR-24-19	Downregulated
miR-24-20	Downregulated
miR-24-21	Downregulated
miR-24-22	Downregulated
miR-24-23	Downregulated
miR-24-24	Downregulated
miR-24-25	Downregulated
miR-24-26	Downregulated
miR-24-27	Downregulated
miR-24-28	Downregulated
miR-24-29	Downregulated
miR-24-30	Downregulated
miR-24-31	Downregulated
miR-24-32	Downregulated
miR-24-33	Downregulated
miR-24-34	Downregulated
miR-24-35	Downregulated
miR-24-36	Downregulated
miR-24-37	Downregulated
miR-24-38	Downregulated
miR-24-39	Downregulated
miR-24-40	Downregulated
miR-24-41	Downregulated
miR-24-42	Downregulated
miR-24-43	Downregulated
miR-24-44	Downregulated
miR-24-45	Downregulated
miR-24-46	Downregulated
miR-24-47	Downregulated
miR-24-48	Downregulated
miR-24-49	Downregulated
miR-24-50	Downregulated
miR-24-51	Downregulated
miR-24-52	Downregulated
miR-24-53	Downregulated
miR-24-54	Downregulated
miR-24-55	Downregulated
miR-24-56	Downregulated
miR-24-57	Downregulated
miR-24-58	Downregulated
miR-24-59	Downregulated
miR-24-60	Downregulated
miR-24-61	Downregulated
miR-24-62	Downregulated
miR-24-63	Downregulated
miR-24-64	Downregulated
miR-24-65	Downregulated
miR-24-66	Downregulated
miR-24-67	Downregulated
miR-24-68	Downregulated
miR-24-69	Downregulated
miR-24-70	Downregulated
miR-24-71	Downregulated
miR-24-72	Downregulated
miR-24-73	Downregulated
miR-24-74	Downregulated
miR-24-75	Downregulated
miR-24-76	Downregulated
miR-24-77	Downregulated
miR-24-78	Downregulated
miR-24-79	Downregulated
miR-24-80	Downregulated
miR-24-81	Downregulated
miR-24-82	Downregulated
miR-24-83	Downregulated
miR-24-84	Downregulated
miR-24-85	Downregulated
miR-24-86	Downregulated
miR-24-87	Downregulated
miR-24-88	Downregulated
miR-24-89	Downregulated
miR-24-90	Downregulated
miR-24-91	Downregulated
miR-24-92	Downregulated
miR-24-93	Downregulated
miR-24-94	Downregulated
miR-24-95	Downregulated
miR-24-96	Downregulated
miR-24-97	Downregulated
miR-24-98	Downregulated
miR-24-99	Downregulated
miR-24-100	Downregulated

miR-24-1/2 clusters are down regulated


**p16<sup>INK4A</sup> protein:**



**p16<sup>INK4a</sup> mRNA**




(Lal et al., PLOS one, 2008)



(Zhou et al., Rheumatology, 2004)







Reverse correlation between miR-24 and p16<sup>INK4a</sup> expression in human cartilage


# What is the impact of miR-24 down regulation on senescence-like phenotype found in OA?




Transfection with antagomir control or against miR-24



RT-qPCR and Elisa for expression of miR-24, p16<sup>INK4a</sup>  
chondrogenic markers and MMP1




Down regulation of miR-24 is sufficient to induce p16INK4A and MMP1




**Hypertrophic phenotype associated with cartilage degeneration in OA**





## Exemple: pathologies osteo-articulaire associées à l'âge



Pathologies ostéo-articulaires du sujet âgé associant la sénescence cellulaire et la perte de l'homéostasie des tissus

# Les CSM (cellules souches mesenchymateuses: cellules souches ostéo-articulaires)

## Caractéristiques

- localisation: M osseuse, placenta, tissu adipeux
- Adhérence au plastique
- marqueurs de surface


positive: CD90 CD105 et CD73 (nestin+)  
negative: CD11b CD14 CD34 CD45

## Fonctions intrinsèques

- Capacité d'autorenouvellement (CfU-F)
- capacité de différenciation ostéo/adipo/chondro

## Fonctions extrinsèques


- Support stromal à d'autres cellules souches (niche HSC) ou à des tissus différenciés
- Immuno-modulation




# MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation


Chang-Jun Li,<sup>1,2</sup> Peng Cheng,<sup>1,3</sup> Meng-Ke Liang,<sup>1</sup> Yu-Si Chen,<sup>1</sup> Qiong Lu,<sup>1</sup> Jin-Yu Wang,<sup>1</sup> Zhu-Ying Xia,<sup>1</sup> Hou-De Zhou,<sup>1</sup> Xu Cao,<sup>2</sup> Hui Xie,<sup>1</sup> Er-Yuan Liao,<sup>1</sup> and Xiang-Hang Luo<sup>1</sup>

<sup>1</sup>Institute of Endocrinology and Metabolism, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China. <sup>2</sup>Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. <sup>3</sup>Department of Gerontology, The First Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, China.







**Figure 1. Aging induces miR-188 expression in BMSCs.** (A–D) Representative images of toluidine blue (T.) staining (A, top) and osteocalcin (Ocn) immunohistochemical staining (A, bottom) and quantification of number and area (Ar) of adipocytes (B and C) and number of osteoblasts (D) in distal femora from 3-month-old and 18-month-old female C57BL/6 mice. Tb. N, trabecular number. Scale bars: 100  $\mu$ m.  $n = 6$  per group. (E) Microarray profiling results of deregulated miRNAs in BMSCs from young and aged mice. (F) qRT-PCR analysis of the levels of miR-188 expression in BMSCs derived from the mice at different ages.  $n = 6$  per group. (G and H) Age-associated changes of miR-188 levels in BMSCs from 85 human females (G) and 85 males (H). Data shown as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$  (B–D, Student's  $t$  test; F, ANOVA).



**Figure 2.** *Mir188*<sup>-/-</sup> mice exhibit reduced age-associated bone loss. (A–H) Representative microcomputed tomography (μCT) images (A) and quantitative μCT analysis of trabecular (B–E) and cortical (F–H) bone microarchitecture in femora from 3-, 12-, and 18-month-old WT and miR-188 knockout (*Mir188*<sup>-/-</sup>) mice. *n* = 6 per group. Tb. BV/TV, trabecular bone volume per tissue volume; Tb. Th, trabecular thickness; Tb. Sp, trabecular separation; Ct. Th, cortical thickness; Ps. Pm, periosteal perimeter; Es. Pm, endosteal perimeter. (I and J) Representative μCT images (I) and quantification of the ratio of bone volume to tissue volume (J) of L4 vertebrae (Vt. BV/TV). *n* = 6 per group. (K and L) Three-point bending measurement of tibia maximum load (K) and stiffness (L). *n* = 5 per group. Data shown as mean ± SD. \**P* < 0.05, \*\**P* < 0.01 (Student's *t* test).




**Figure 3. *Mir188*<sup>-/-</sup> mice show higher osteoblastic bone formation and lower marrow fat accumulation in aged mice.** (A) Representative images of calcein double labeling of trabecular (Tb), endosteal (Eb), and periosteal bone (Pb) with quantification (B–D) of bone formation rate per bone surface (BFR/BS) in femora of 18-month-old WT and *Mir188*<sup>-/-</sup> mice. Scale bar: 50  $\mu$ m.  $n = 6$  per group. (E) Representative images of toluidine blue staining with quantification of number and area of adipocytes in distal femora (F and G). Scale bar: 100  $\mu$ m. (H) Representative images of osteocalcin immunohistochemical staining with quantification of number of osteoblasts in distal femora (I). Scale bar: 100  $\mu$ m.  $n = 6$  per group. (J) Representative images of Oil Red O staining of lipids (top) and Alizarin Red S staining of matrix mineralization (bottom) in BMSCs from *Mir188*<sup>-/-</sup> mice and WT mice cultured in adipogenesis induction medium for 14 days and osteogenesis induction medium for 21 days, respectively. Scale bar: 100  $\mu$ m. Data are representative of 3 independent experiments. Data shown as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$  (Student's  $t$  test).




**Figure 5. Mice with BMSC-specific overexpression of miR-188 using aptamer delivery system exhibit reduced bone formation and increased marrow fat accumulation.** (A) qRT-PCR analysis of levels of miR-188 expression in BMSCs of mice with aptamer delivery. NC, negative control.  $n = 6$  per group. (B-I) Representative  $\mu$ CT images (B) and quantitative  $\mu$ CT analysis of trabecular (C-F) and cortical bone (G-I) microarchitecture in femora from aptamer-treated mice.  $n = 10$ . (J and K) Three-point bending measurement of femur maximum load (J) and stiffness (K).  $n = 5$  per group. (L-N) Calcein double labeling-based quantification of bone formation rate per bone surface (BFR/BS) in femora.  $n = 5$  per group. (O-R) Representative images of H&E staining (O, top) and osteocalcin immunohistochemical staining (O, bottom) and quantification of number and area of adipocytes (P and Q) and number of osteoblasts (R) in distal femora. Scale bars: 100  $\mu$ m (B), 50  $\mu$ m (O). Data shown as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$  (ANOVA).







**Figure 6. MiR-188 promotes adipogenic differentiation of BMSCs.** (A) qRT-PCR analysis of the relative levels of miR-188 expression in BMSCs cultured in adipogenesis induction medium (0.5 mM 3-isobutyl-1-methylxanthine, 5  $\mu$ g/ml insulin, and 1  $\mu$ M dexamethasone) for the days as indicated.  $n = 5$  per group. (B) qRT-PCR analysis of the relative levels of miR-188 expression in BMSCs transfected with 10  $\mu$ M agomiR-188, antagomiR-188, or their negative controls. NC, negative control.  $n = 5$  per group. (C and D) Representative images of Oil Red O staining of lipids (C) and quantification of the number of spots (D) in BMSCs cultured in adipogenesis induction medium for 14 days. Scale bar: 100  $\mu$ m. (E and F) qRT-PCR analysis of the relative levels of *Pparg* (E) and *Fabp4* (F) mRNA expression in BMSCs cultured in adipogenesis induction medium for 48 hours. (G) Microarray profiling results of dysregulated adipogenic genes in WT and *Mir188*<sup>-/-</sup> mouse-derived BMSCs cultured in adipogenesis induction medium for 48 hours. Data shown as mean  $\pm$  SD. \* $P < 0.05$ , \*\* $P < 0.01$  (ANOVA).




**Figure 8. MIR-188 directly targets HDAC9 and RICTOR.** (A) Western blot analysis of the relative levels of HDAC9, RICTOR, PTEN, ZNF281, GLIS3, and EFN2 protein expression in BMSCs transfected with agomiR-188 and antagomiR-188.  $\beta$ -Actin was used as loading control. Data are representative of 3 independent experiments. (B) Schematic of miR-188 putative target sites in mouse *Hdac9* and *Rictor* 3'-UTR. CDS, coding sequence. (C-E) BMSCs were transfected with luciferase reporter carrying WT or MUT 3'-UTR of the *HDAC9* gene (WT-HDAC9-3'-UTR and MUT-HDAC9-3'-UTR) (C) WT1-Rictor-3'-UTR and MUT1-Rictor-3'-UTR (D), WT2-Rictor-3'-UTR and MUT2-Rictor-3'-UTR (E), respectively, and cotransfected with agomiR-188 or agomiR-NC. Effects of miR-188 on the reporter constructs were determined at 48 hours after transfection. Firefly luciferase values, normalized for renilla luciferase, are presented.  $n = 3$  per group. (F) Western blot analysis of HDAC9 and RICTOR protein expression in BMSCs from different mice as indicated. Data are representative of 3 independent experiments. Data shown as mean  $\pm$  SD. \* $P < 0.01$  vs. MUT-pGL3-HDAC9 or -RICTOR (Student's *t* test).



**Figure 9. Injection of aptamer-antagomiR-188 into bone marrow stimulates bone formation and decreases marrow fat accumulation in aged mice.** (A) qRT-PCR analysis of the levels of miR-188 expression in BMSCs of mice with BMSC-specific antagomiR-188 delivery. Aptamer-antagomiR-188 was injected into femoral bone marrow cavity of 15-month-old mice twice per month for 3 months. NC, negative control. (B-I) Representative  $\mu\text{CT}$  images (B) and quantitative  $\mu\text{CT}$  analysis of trabecular (C-F) and cortical (G-I) bone microarchitecture in femora from aptamer-treated mice.  $n = 10$  per group. (J and K) Three-point bending measurement of femur maximum load (J) and stiffness (K).  $n = 5$  per group. (L-N) Calcein double labeling-based quantification of



**ACTION à distance des microRNAs sur le vieillissement tissulaire**






## Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells

Sylvia Weilner,<sup>1,2,3,\*</sup> Elisabeth Schraml,<sup>1,\*</sup> Matthias Wieser,<sup>1,4</sup> Paul Messner,<sup>5</sup> Karl Schneider,<sup>1,2</sup> Klemens Wassermann,<sup>1,2</sup> Lucia Micutkova,<sup>6</sup> Klaus Fortschegger,<sup>7</sup> Andrea B. Maier,<sup>8,9</sup> Rudi Westendorp,<sup>10</sup> Heinrich Resch,<sup>11</sup> Susanne Wolbank,<sup>2,13</sup> Heinz Redl,<sup>2,13</sup> Pidder Jansen-Dürr,<sup>6</sup> Peter Pietschmann,<sup>12</sup> Regina Grillari-Voglauer<sup>1,3,4</sup> and Johannes Grillari<sup>1,3,13</sup>


<sup>1</sup>Department of Biochemistry, <sup>2</sup>OKU – University of Applied Sciences, <sup>3</sup>Department of Biotechnology, <sup>4</sup>Department of Cell Biology, <sup>5</sup>Department of Cell Biology, <sup>6</sup>Department of Cell Biology, <sup>7</sup>Department of Cell Biology, <sup>8</sup>Department of Cell Biology, <sup>9</sup>Department of Cell Biology, <sup>10</sup>Department of Cell Biology, <sup>11</sup>Department of Cell Biology, <sup>12</sup>Department of Cell Biology, <sup>13</sup>Department of Cell Biology

mal stem cells where it inhibits osteogenic differentiation by knocking down its target Frizzled-3. Therefore, we suggest that microvesicular miR-31 in the plasma of elderly might play a role in the pathogenesis of age-related impaired bone formation and that miR-31 might be a valuable plasma-based biomarker for aging and for a systemic environment that does not favor cell-based therapies whenever osteogenesis is a limiting factor.




**Fig. 2** miR-31 is enriched in CD63-positive microvesicles of senescent endothelial cells. (A) miR-31 expression is upregulated in senescent (S) versus early quiescent passage (Y) HUVECs ( $N = 3$ ) as analyzed by qPCR. (B) miR-31 was detected at high levels after RNA isolation from supernatants (SN) ( $N = 3$ ) and (C) from MVs of senescent (S) versus early quiescent (Y) passage HUVECs ( $N = 3$ ). (D) Significantly increased miR-31 levels in tMV fraction of senescent endothelial cells compared with the CD63<sup>-</sup> fraction. (E) Localization of miR-31 within MVs. Arrowhead indicates immunogold-labeled anti-DIG antibody after hybridizing a DIG-labeled anti-miR-31 probe to permeabilized MVs. \*\*\*:  $P < 0.001$  in comparison with control. Data of this figure are presented as mean values  $\pm$  SD and were statistically analyzed using Student's t-test.

L







## Article

# MicroRNAs Both Promote and Antagonize Longevity in *C. elegans*


Alexandre de Lencastre,<sup>1</sup> Zachary Pincus,<sup>1</sup> Katherine Zhou,<sup>1</sup> Masaomi Kato,<sup>1</sup> Siu Sylvia Lee,<sup>2</sup> and Frank J. Slack<sup>1,\*</sup>

<sup>1</sup>Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06511 USA


<sup>2</sup>Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY 14850, USA

metabolism, immunity, life span, and cancer [3]—and target predictions suggest that they may regulate thousands of human genes [4]. Still, only a small number of the thousands of known miRNAs have been implicated in a specific biological function, whereas the role of the vast majority of miRNAs remains unknown. Mutations in the developmental timing genes *lin-4* (a founding member of the miRNA family) and its


## Utilisation de *C.elegans*, un nématode



## Cycle de vie de *C. elegans*



## Identification et caractérisation de mutants de *C. elegans*



(Spe-9)

Table 1. Summary of Largest Expression Changes of miRNAs with Aging

miRNA	N2	<i>daf-2(e1370)</i>	Homology
<b>Most Upregulated with Aging</b>			
miR-246	5.90	9.46	
miR-71	4.04	4.21	
miR-34	3.93	3.28	miR-34
miR-253	3.31	1.44	miR-220
miR-238	2.88	2.43	miR-12
miR-239b	2.85	6.37	miR-12
miR-239a	2.15	1.91	miR-12
<b>Most Downregulated with Aging</b>			
let-7	-7.38	-5.39	let-7
miR-41	-6.78	-2.34	
miR-70	-5.70	-3.80	
miR-252	-5.02	-2.22	
miR-62	-4.30	-2.91	
miR-36	-4.10	-2.62	
miR-59	-3.56	-1.41	
miR-1829b	-3.44	-2.31	
miR-236	-3.20	-3.69	miR-200b
miR-37	-3.20	-2.15	
miR-237	-3.14	-5.70	lin-4, miR-125
miR-793	-2.95	-2.13	
miR-43	-2.72	-2.10	
miR-65	-2.65	-1.76	
miR-40	-2.59	-2.50	
miR-77	-2.27	-1.48	
miR-79	-2.22	-4.93	miR-9
miR-81	-2.18	-1.88	
miR-82	-2.17	-1.82	
miR-259	-2.16	-1.37	
miR-38	-2.14	-1.84	
miR-64	-2.11	-1.61	
miR-35	-2.06	-1.81	
miRNA	Day 0	miRNA	Day 10
<b>Most Upregulated in <i>daf-2(e1370)</i></b>			
miR-237	2.94	miR-62	3.00
miR-49	2.26	miR-49	2.93
miR-253	2.21	miR-252	2.22
miR-44	2.05	miR-231	2.19
miR-45	2.05		
miR-62	2.03		
<b>Most Downregulated in <i>daf-2(e1370)</i></b>			
miR-1829c	-4.49	miR-242	-2.24
miR-239b	-3.40		
miR-259	-2.80		
miR-246	-2.04		
miR-85	-2.00		




Figure 5. miR-239 and miR-71 Function through the IGF-1/Insulin-like and the DNA Damage Checkpoint Pathways

(A) The long life span of *mir-239(nDf62)* is suppressed by *daf-16(RNAi)* but is unaffected by control (empty vector) RNAi. *mir-239(nDf62)* does not further enhance life span on *daf-2(RNAi)*, suggesting that they function in the same pathway.


(B and C) The long life span of *daf-2(RNAi)* is partially suppressed by *mir-71(n4115)*, and *daf-16(RNAi)* does not further decrease the life span of *mir-71(n4115)*, suggesting that miR-71 functions in the same pathway as DAF-2 and DAF-16.

(D) miR-71 additionally functions in the DNA damage checkpoint pathway. *mir-71(n4115)* fully suppresses the longevity induced by RNAi against CDC-25.1, a factor of the DNA damage checkpoint pathway.

All life-span assays were conducted at 20°C. Statistics are shown in Table S5.

D

### IGF1/Insulin-Like Pathway





## CONCLUSIONS:

- 1- Les miRs sont comme des régions codantes soumis à un contrôle épigénétique
- 2- Conservation des séquences des miRs inter-especes (pression de sélection/ évolution)
  - 62% similaires entre C.elegans et la drosophile
  - 55% similaires entre C.elegans et humain
- 3- Beaucoup de travail sur l'identification des cibles des miRs et de leur véritable mode d'action
- 4- identification de miRs régulant chez les mammifères le vieillissement général?
- 5- en particulier des miRs régulant en systémique le vieillissement tissulaire

# Acknowledgments



Didier Philipot  
David Guérit  
Dr Paul Chuchana  
Dr Farida Djouad  
Dr Danièle Noël  
Pr Christian Jorgensen  
INSERM U1183



Dr Charles Lecellier  
Dr Jacques Piette



SERVIZIO SANITARIO REGIONALE  
EMILIA - ROMAGNA  
Istituto Ortopedico Rizzoli di Bologna  
Istituto di Ricovero e Cura a Carattere Scientifico



Dr Rosa Maria Borzi  
Dr Eleonora Olivotto  
Dr Daniela Platano



Immuno-rhumatologie et thérapeutique des  
maladies osseuses et articulaires

[www.irmb.com](http://www.irmb.com)

